A Single-Center Phase 3b Trial Investigating the Long-term Effect on Intestinal Absorption, Nutritional Status and Long-Term Safety of treatment with Glepaglutide in Patients with Short Bowel Syndrome (SBS)
Latest Information Update: 24 Nov 2024
At a glance
- Drugs Glepaglutide (Primary)
- Indications Intestinal failure; Short bowel syndrome
- Focus Registrational; Therapeutic Use
- Acronyms EASE SBS 4; EASE-4
- Sponsors Zealand Pharma
- 27 Feb 2024 According to a Zealand Pharma media release, the company expects to receive notification of a PDUFA date in the coming weeks following acceptance of the filing.
- 22 Dec 2023 According to a Zealand Pharma media release, the company has submitted NDA to US FDA for glepaglutide, for the treatment of adult patients with short bowel syndrome (SBS) dependent on parenteral support, based on data from EASE clinical trial program (EASE-1, EASE-2, EASE-3 and EASE-4).
- 28 Sep 2023 Status changed from active, no longer recruiting to completed.